Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Prepaid Assets (2021 - 2025)

Historic Prepaid Assets for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $14.9 million.

  • Krystal Biotech's Prepaid Assets rose 2786.31% to $14.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $14.9 million, marking a year-over-year increase of 2786.31%. This contributed to the annual value of $14.9 million for FY2025, which is 2786.31% up from last year.
  • According to the latest figures from Q4 2025, Krystal Biotech's Prepaid Assets is $14.9 million, which was up 2786.31% from $17.2 million recorded in Q3 2025.
  • Over the past 5 years, Krystal Biotech's Prepaid Assets peaked at $17.2 million during Q3 2025, and registered a low of $2.2 million during Q2 2021.
  • Moreover, its 5-year median value for Prepaid Assets was $6.0 million (2023), whereas its average is $7.5 million.
  • Per our database at Business Quant, Krystal Biotech's Prepaid Assets surged by 1047.71% in 2022 and then soared by 15828.84% in 2025.
  • Krystal Biotech's Prepaid Assets (Quarter) stood at $4.2 million in 2021, then increased by 10.48% to $4.6 million in 2022, then surged by 45.53% to $6.7 million in 2023, then surged by 73.83% to $11.7 million in 2024, then rose by 27.86% to $14.9 million in 2025.
  • Its Prepaid Assets was $14.9 million in Q4 2025, compared to $17.2 million in Q3 2025 and $16.9 million in Q2 2025.